Same as the former, our previous study achieved consistent outcomes when comparing toripalimab (anti-PD-1 mono-antibody) combination therapy with single chemotherapy in advanced NSCLC patients progressed on EGFR-TKIs (15). Here, EGFR is linked to non-small cell lung carcinoma.